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Abstract
Erythroid enucleation is critical for terminal differentiation of red blood cells, and involves
extrusion of the nucleus by orthochromatic erythroblasts to produce reticulocytes. Due to
the difficulty of synchronizing erythroblasts, the molecular mechanisms underlying the enu-
cleation process remain poorly understood. To elucidate the cellular program governing
enucleation, we utilized a novel chemical screening approach whereby orthochromatic cells
primed for enucleation were enriched ex vivo and subjected to a functional drug screen
using a 324 compound library consisting of structurally diverse, medicinally active and cell
permeable drugs. Using this approach, we have confirmed the role of HDACs, proteasomal
regulators and MAPK in erythroid enucleation and introduce a new role for Cyclin-depen-
dent kinases, in particular CDK9, in this process. Importantly, we demonstrate that when
coupled with imaging analysis, this approach provides a powerful means to identify and
characterize rate limiting steps involved in the erythroid enucleation process.
Introduction
Erythropoiesis involves the gradual progression of hematopoietic stem cells into mature red
blood cells. During terminal differentiation, proerythroblasts undergo several differentiation-
linked cell divisions producing basophilic, polychromatic and then orthochromatic daughter
erythroblasts. The orthochromatic cells ultimately exit from the cell cycle and extrude their
nuclei in a process termed erythroid enucleation. The enucleation event involves multiple path-
ways and shares some similarities with cytokinesis and apoptosis (for reviews see Keerthivasan
et al [1] and Ji et al [2]); however, experimental results have been variable due to the difficulty
of synchronizing erythroblasts and the inability to exclude indirect effects of inhibitors on the
proliferation of earlier erythroblasts. In vivo investigations have also been hindered by the
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necessity of enucleation for organismal survival with genetic knockdown of key genes often
associated with either high redundancy or embryonic lethality. Therefore, our understanding
of the molecular mechanisms employed during enucleation remains poor.
In this study we isolated orthochromatic erythroblasts poised to enucleate, and exposed
them to a compound screen in order to probe the cellular program governing erythroid enucle-
ation. Although chemical inhibitors used in isolation can be misleading due to off target effects,
the use of a large and well-validated library can circumvent this issue, and overcome many of
the problems of gene targeting by allowing acute blocking of pathways. By applying stringent
criteria such as effects from multiple drugs targeting the same pathways, this screening
approach can identify new components of previously known pathways, mechanistic insights
into cellular process that these pathways affect, and new regulators of enucleation. Here, using
this approach we confirm the role of HDACs, proteasomal regulators and MAPK in erythroid
enucleation and introduce a new role for Cyclin-dependent kinases, in particular CDK9, in this
process.
Materials and Methods
Materials
Phenylhydrazine hydrochloride was purchased from Aldrich Chemistry. CD44- PE-Cy7 anti-
mouse antibodies and the BrdU Flow Kit were purchased from BD Pharmingen. Ter119-Alexa
Fluor 647 anti-mouse antibodies were purchased from Biolegend. Hoechst 33342 was pur-
chased from Invitrogen. Propidium iodide (PI) was purchased fromMerck. Dimethyl sulfoxide
(DMSO) was purchased from Calbiochem. Rapid Diff stain was purchased from Australian
Biostain. Cytochalasin D was purchased from Sigma Aldrich. The 324 compound library and
follow up compounds were purchased from Selleck Chemicals.
Animal experiments and orthochromatic erythroblast isolation
All animal procedures were approved by the Peter MacCallum Cancer Centre Animal experi-
mentation Ethics Committee. To induce stress erythropoiesis C57Bl/6 mice at 6–12 weeks of
age were administered intraperitoneal injections of phenylhydrazine hydrochloride (60μg/g)
on day 0 and day 1 of the experiments. On day 4 of the experiments, cells were harvested from
mouse spleens. Using the plunger of a syringe, spleens were pressed through a cell strainer
(70μm) and further dissociated into single cell suspensions in PBS (2% FBS) using a 1ml
pipette. Cells were stained for Hoechst 33342 (Invitrogen) in pre-warmed alpha-MEMmedia
(containing 10% FBS, 1% Sodium Pyruvate, 1% Glutamax) for 20–30min in a waterbath at
37°C. Cells were subsequently washed and stained for CD44 and Ter119 for 15min on ice. All
Hoechst negative (enucleated) cells were excluded from the sort. Orthochromatic erythroblasts
were isolated based on their Ter119 (high) and CD44 (low) expression (Fig 1A) by FACS Aria
II special order system (BD) using the FACS Diva software (BD). PI was used to exclude dead
cells from the sort. Cell cycle analysis was performed by bromodeoxyuridine (BrdU) incorpo-
ration in vitro according to manufacturers specification. Briefly, BrdU (10μM final concentra-
tion) was added to the culture medium (alpha-MEMmedia supplemented with 10% FBS, 1%
Sodium Pyruvate and 1% Glutamax) for a 1h incubation period at 37°C. Cells were then fixed
and permeabilized and subsequently treated with DNase. Exposed BrdU was visualized with a
FITC-conjugated anti-BrdU antibody. 7-amino-actinomycin D (7-AAD) solution was used for
total DNA staining. Cells were analyzed with the FACS LSR II (BD) using the FACS Diva soft-
ware (BD).
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Compound screen
Orthochromatic erythroblasts (30,000 cells/well) were incubated in 96-well plates (one spleen
of a PHZ treated mouse was required per 96-well plate) in the presence of the compounds
(1μM) in alpha-MEMmedia (supplemented with 10%FBS, 1% Sodium Pyruvate and 1%
Fig 1. Isolation and characterization of orthochromatic erythroblasts. (A)Orthochromatic erythroblasts were isolated (gate highlighted in red) from the
spleen by FACS (Aria II) based on their Ter119 versus CD44 expression. Hoechst negative cells were excluded from the sort. (B) Cell cycle analysis was
performed on the sorted orthochromatic erythroblasts based on in vitro BrdU incorporation and 7-AAD staining and compared to the less mature (“late”)
erythroblasts (gate highlighted in blue in Fig 1A). (C) Enucleation in the sorted population was quantified hourly for 6 hours using. Data are means (+/− SD) of
3 independent experiments. Enucleation rate was also compared between 5 and after 10 hours after the FACS sort. Data are means (+/− SD) of 4
independent experiments. *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001 (paired student’s t-test). (D) The extent of enucleation was assessed by FACS
LSR II shown here for negative and positive plate controls (DMSO and Cytochalasin D (Cyt.D) respectively). Propidium iodide (PI) was added to exclude
dead cells from the analysis and to reveal potentially cytotoxic effects of the compounds.
doi:10.1371/journal.pone.0142655.g001
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Glutamax) in a final volume of 200μl/well for 5h at 37°C. Each assay plate held negative control
wells containing DMSO alone, the compound solvent, as well as positive control wells with
cytochalasin D, an inhibitor of erythroid enucleation [3, 4], so as to enable quality control and
standardization between each plate. Enucleation was quantified by FACS LSR II (BD) using the
FACS Diva software (BD). Net percentage of enucleation was derived by dividing the number
of enucleated cells (Ter119+/Hoechst−) by the sum of enucleated cells and erythroblasts
(Ter119+/Hoechst+), and by subsequently multiplying the quotient by 100. PI was used to
exclude dead cells from the analysis. The screen was run in batches and the experiment
repeated on a subsequent plate on a separate day. The raw data was normalized using the plate
median and transformed into z-scores.
Cytospins
Nuclei were separated from enucleated reticulocytes mechanically by trituration (gently pipett-
ing up and down). 30,000–60,000 orthochromatic erythroblasts were spun onto slides at
320rpm for 4min. Slides were air-dried before fixing with MeOH, stained with Rapid Diff and
quantitated manually under the microscope (Olympus BX-51, 100x/1.40 NA oil objective).
Results and Discussion
The process of erythroblast enucleation occurs within a 10 minute period [5] and is not syn-
chronized, making it challenging to interpret effects of drugs and shRNA studies. In this study
we avoided indirect effects of the compounds on earlier proliferating erythroblasts by isolating
orthochromatic erythroblasts, poised to enucleate, to expose to a 324-compound screen.
Isolation of orthochromatic erythroblasts and enucleation assay
Orthochromatic erythroblasts were isolated from the spleen based on expression of Ter119 and
CD44 [6] (Fig 1A) (a cytospin of unsorted spleen cells for comparison is shown in S1 Fig). Cell
cycle analysis based on BrdU incorporation confirmed the enrichment of orthochromatic
erythroblasts (88.7 ± 3.5% of the isolated erythroblasts were non-proliferating erythroblasts)
(Fig 1B). The enucleation rate of the isolated erythroblasts determined hourly increased line-
arly with time and peaked to around 70 ± 10.5% after 6 hours in media, with no statistical dif-
ference observed in enucleation rate between 5 and 10 hours (Fig 1C). Enucleation was
quantified by FACS analysis. An example of this analysis is shown in Fig 1D using the negative
and positive plate controls. In the presence of the vehicle control (DMSO) erythroblasts enucle-
ate (Ter119 positive, Hoechst negative) but in the presence of Cytochalasin D (1μM) enucle-
ation is blocked (Fig 1D). This is also visible in the forward scatter (FSC) versus side scatter
(SSC) dot plots as enucleated cells (reticulocytes) are smaller than orthochromatic erythro-
blasts. The shift in FSC and SSC profiles may also indicate that the erythroblasts change shape
consistent with the known action of the actin inhibitor on cell morphology. Propidium Iodide
(PI) was added to exclude dead cells from the analysis and also to help distinguish whether
enucleation was blocked because of a specific mechanism being inhibited or as a result of
cytotoxicity.
Chemical screen assay identifies known and novel targets
The Selleck library utilized in our screen contained 324 structurally diverse, medicinally active,
cell permeable drugs with multiple drugs targeting the same pathways (Fig 2A). To minimize
non-specific effects, each compound was tested at a final concentration of 1μM. The screen
was run in batches in 96-well microtiter plates and the experiment repeated on a subsequent
Chemical Screen Targeting Erythroid Enucleation
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B
Fig 2. Chemical screen targeting erythroid enucleation. (A) List of molecules targeted in the chemical
screen. (B) For the compound screen orthochromatic erythroblasts were isolated by FACS and subsequently
incubated in 96-well plates in the presence of the compounds for 5h. The extent of enucleation was assessed
by FACS LSR II. Graphs showing that the raw data between the duplicate assay plates are reproducible. (C)
Graph showing compounds confirmed to significantly (paired student’s t-test) inhibit enucleation compared to
Chemical Screen Targeting Erythroid Enucleation
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plate on a separate day. Correlation coefficients showed that the raw data between the two
independent biological repeats was highly reproducible (Fig 2B). The raw data (S1 Table) was
normalized and transformed into z-scores (S2 Fig). Compounds demonstrating z-scores<−1
in either replicate were selected as potential hits (S2 Fig) and were tested independently (n = 4)
for their ability to inhibit enucleation at 1μM concentrations. Inhibition of enucleation was
confirmed for 25 compounds (Fig 2C).
Validating our approach, one of the most significant families of hits centered on HDAC
inhibitors (Fig 2C). Previous studies have implicated the importance of chromatin condensa-
tion for terminal erythroid differentiation [7–9]; but our findings that HDAC inhibitors
affected erythroblasts after exit of the cell cycle, when chromatin condensation should have
ceased, suggests that other, non-histone HDAC targets could be involved in the extrusion of
the nucleus at this late stage of enucleation. Similarly, we confirm a role for MAPK p38 in ery-
throid enucleation (Fig 2C). MAPK p38 upregulates p21 and retinoblastoma protein (Rb)[10],
both of which are crucial regulators of erythroid enucleation [11, 12]. Our findings suggest that
MAPK p38 might play additional post-translational roles in enucleation.
Proteasome inhibition leads to nuclear segmentation of orthochromatic
erythroblasts and decreased enucleation
Three out of five compounds targeting the proteasome inhibited erythroid enucleation (Fig
2C). A potential requirement for the proteasome in erythroid enucleation has been highlighted
in a study by Chen et al [13]. This study showed that enucleation of erythroblasts infected with
the anemia-inducing strain of Friend-virus was decreased by up to 40% in the presence of pro-
teasome inhibitors. Our data supports this observation and extends it to determine the cellular
effects of proteasome inhibitors on enucleating erythroblasts. Here we show that up to 30% of
cytospun enucleating erythroblasts treated with proteasome inhibitors displayed a nuclear seg-
mentation phenotype with the nuclear compartments connected by DNA bridges (Fig 3C).
Interestingly, incubating orthochromatic erythroblasts with both proteasome inhibitors and
the actin inhibitor Cytochalasin D resulted in arrest of enucleation but prevented segmentation
of the nucleus (Fig 3D) suggesting that a proteasome-mediated mechanism may regulate the
spatial and/or temporal control of the contractile apparatus required for efficient nuclear extru-
sion. Alternatively, the Cytochalasin D block may occur “upstream” of the proteasome inhibi-
tor block thus leading to a dominant epistatic phenotype. Furthermore, quantitative analysis
revealed that by 10 hours, Bortezomib treated erythroblasts reached normal (vehicle control)
levels of enucleation (Fig 3E), indicating that proteasome inhibitors cause a delay rather than
an arrest of enucleation.
Chemical screen identifies CDK9 as a novel regulator of enucleation
What of new targets? Our screen and follow up experiments indicate that CDK activity is
important for erythroid enucleation (Fig 2C). Flavopiridol and SNS-032 were among the com-
pounds that inhibited enucleation most efficiently and in a concentration dependent manner
(Fig 4A). Since all the CDK inhibitors that resulted in an arrest of enucleation (S3 Fig) are
strong inhibitors of both CDK7 and CDK9, Dinaciclib (inhibits CDK9 but not CDK7) was
tested for its ability to inhibit enucleation to further specify which of the CDKs is likely to play
a role in the extrusion of the nucleus. Dinaciclib inhibited enucleation in a concentration
the vehicle control (DMSO). Data are means (+/− SD) of 4 independent experiments. *P< 0.05, **P< 0.01,
***P< 0.001, ****P< 0.0001 (paired student’s t-test).
doi:10.1371/journal.pone.0142655.g002
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Fig 3. Characterization of a role of the proteasome in erythroid enucleation. (A)Orthochromatic erythroblasts were cytospun immediately (0h) after
FACS enrichment, Rapid Diff stained and imaged with the Olympus BX-51 microscope (100x/1.40 NA oil objective) using the Spot Advanced software
(version 4.7). For quantitative analysis of the cytospins cells were manually examined and assigned a morphological class as per illustration. Data are means
(+/− SD) of 4 independent experiments (112–541 cells per experiment were enumerated). (B)Orthochromatic erythroblasts were incubated in media
containing DMSO (vehicle control) or Cytochalasin D (1μM) for 5h and subsequently cytospun. For quantitative analysis 355–740 cells per experiment were
Chemical Screen Targeting Erythroid Enucleation
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dependent manner at nanomolar concentrations (Fig 4A) confirming that CDK9 activity is the
major CDK activity required for nuclear extrusion. Morphological analysis revealed that Flavo-
piridol, SNS-032 and Dinaciclib arrested extrusion of the nucleus in enucleating cells (Fig 4B).
Further supporting the notion that CDK9 activity is important for erythroid enucleation, PIK-
75, a dual inhibitor of PI3K and CDK9 [14, 15], but no other PI3K inhibitor, inhibited enucle-
ation and phenocopied the enucleation arrest caused by Flavopiridol and SNS-032 (S4 Fig).
Furthermore, percentages of enucleated cells treated with CDK inhibitors did not increase
from 5 to 10 hours in culture (Fig 4C), indicating that CDK inhibitors cause an arrest of enucle-
ation rather than a delay. The viability of erythroblasts treated with the CDK inhibitors was not
affected with enucleation rates recovering after washout of the CDK inhibitors (Fig 4D).
Interestingly, knockdown of CDK9, the kinase subunit of the transcription factor pTEF-b,
results in disruption of primitive erythropoiesis in zebrafish and treatment of human CD34+
cells with Flavopiridol, a CDK9 inhibitor, blocked early erythroid differentiation [16]. Our
study indicates that CDK9 is also likely to function late in terminal differentiation during
nuclear extrusion. CDKs are known to regulate the cell cycle, with CDK9 shown to also play
important roles in the regulation of RNA transcription [17]. Because orthochromatic erythro-
blasts are said to have exited the cell cycle and since chromatin is highly condensed at this stage
of development, RNA transcription is curbed [18]. CDKs and in particular CDK9 are likely
then to regulate enucleation through other mechanisms. Consistent with this notion, treatment
with RNA polymerase II inhibitor α–amanitin did not affect enucleation (S5 Fig). The revers-
ibility of inhibition by CDK inhibitors and other compounds used in this study such as Cyto-
chalasin D provide powerful tools to synchronize erythroblasts at key steps of enucleation and
following release of inhibition allow the detailed biochemical and cellular study of the individ-
ual steps of enucleation. Combined with proteomics and RNAi studies, this will provide a use-
ful platform to assess the potential mechanism of CDK functions in erythroid enucleation.
Microtubule and PI3K activity is not required for the actual extrusion of
the nucleus during erythroid enucleation
None of the 5 inhibitors targeting microtubules (MTs) inhibited enucleation in our screen. The
question of whether MTs are critical for erythroid enucleation has been widely discussed and
remains controversial [3, 4, 19, 20]. Similarly, despite evidence that PI3K activity is involved in
the establishment of cell polarity in late stage erythroblasts and that PI3K inhibitors delay enu-
cleation [21], we found only one of the 17 compounds targeting PI3Ks to inhibit enucleation
(Fig 2C), and this compound, PIK-75, also inhibits CDK9. However, earlier processes that are
thought to involve MT and PI3K, such as the movement of the nucleus to one side of the cell,
may not have been addressed in our screen since over 33% of the isolated erythroblasts dis-
played polarized nuclei at 0h already (Fig 3A).
Conclusion
Taken together, our chemical screening approach allowed us to directly question pathways
involved in the extrusion of the nucleus during erythroid enucleation. Of note, the vast
enumerated for the 5h time point in DMSO; 640–712 cells per experiment for the 5h time point in 1μMCytochalasin D. Data are means (+/− SD) of 4
independent experiments. (C) Cytospins and quantitative analysis of orthochromatic erythroblasts treated with the indicated proteasome inhibitors (1μM) for
5h. Data are means (+/− SD) of 3 independent experiments (347–585 cells per experiment treated with Bortezomib; 422–428 cells per experiment treated
with MLN9708; 351–698 cells per experiment treated with MLN2238). (D)Quantitative analysis of cytospun orthochromatic erythroblasts treated with
Bortezomib and Cytochalasin D (1μM each). Data are means (+/− SD) of 3 independent experiments (448–516 cells per experiment treated with Bortezomib
in combination with Cyt.D). (E)Graph showing percentages of enucleation after 5h and 10h in the presence of Bortezomib (1μM). Data are means (+/− SD) of
3 independent experiments analyzed using FACS LSR II. *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001 (paired student’s t-test).
doi:10.1371/journal.pone.0142655.g003
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Fig 4. Characterization of a role of CDK activity in erythroid enucleation.Orthochromatic erythroblasts were isolated from the spleen using FACS, and
incubated in the presence of the indicated compounds for 5h. (A)Graphs showing percentages of enucleation in the presence of the indicated compounds at
the indicated concentrations. Data are means (+/− SD) of 3–4 independent experiments analyzed using FACS LSR II (*P< 0.05, **P< 0.01, ***P< 0.001,
****P< 0.0001 (paired student’s t-test)). (B) Cytospins and quantitative analysis of orthochromatic erythroblasts treated with the indicated inhibitors for 5h.
Data are means (+/− SD) of 3 independent experiments (364–904 cells per experiment treated with Flavopiridol (1μM); 499–730 cells per experiment treated
Chemical Screen Targeting Erythroid Enucleation
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majority of enucleation inhibitors (with the notable exception of proteasome inhibitors) show
a similar enucleation arrest phenotype at the nuclear extrusion step. This suggests that the pro-
tein activities they block either all block the same necessary pathway required to advance past
the extrusion step, or alternatively that a common checkpoint is elicited during enucleation
when the activity of any of these proteins is aberrant. Finally, our studies implicate CDK9 as an
important regulator of enucleation and future work will involve elucidating the critical CDK9
targets required for enucleation. In conclusion, our approach is highly suited to rapidly and
directly testing novel classes of inhibitors for effects on enucleation and provides the opportu-
nity of carrying out unbiased chemical screens to identify novel rate limiting steps and targets
in the enucleation process.
Supporting Information
S1 Fig. Cytospin of unsorted spleen cells. Image of unsorted, cytospun spleen cells harvested
from PHZ treated mice. Scale bar = 20μm.
(PDF)
S2 Fig. Analysis of the 324 compound screen targeting erythroid enucleation. Orthochro-
matic erythroblasts were isolated by FACS and subsequently incubated in 96-well plates in the
presence of the compounds for 5h. The extend of enucleation was assessed by FACS. (A) Raw
data was normalized using the plate median and transformed into z-scores. (B) 37 compounds
demonstrating z-scores smaller than -1 in either replicate were selected as potential hits and
further validated.
(PDF)
S3 Fig. CDK inhibitors targeting erythroid enucleation. Graph showing CDK inhibitors
(1μM) that resulted in inhibition of enucleation (marked in pink) compared to inhibitors that
did not result in inhibition of enucleation (marked in blue).
(PDF)
S4 Fig. Characterization of the effects of PI3K/CDK9 inhibitor PIK-75.Orthochromatic
erythroblasts were isolated from the spleen using FACS, and incubated in the presence of PIK-
75 for 5h. (A) Graph showing percentages of enucleation in the presence of PIK-75 at the indi-
cated concentrations. Data are means (+/− SD) of 4 independent experiments analyzed using
FACS LSR II (P< 0.05, P< 0.01, P< 0.001, P< 0.0001 (paired student’s t-test)). (B)
Cytospins and quantitative analysis of orthochromatic erythroblasts treated with PIK-75 for 5h
(662–689 cells per experiment treated). Scale bar = 10μm.
(PDF)
S5 Fig. Characterization of the effects of RNA-Polymerase II inhibitor. Orthochromatic
erythroblasts were isolated from the spleen using FACS, and incubated in the presence of the
vehicle control (DMSO) or alpha-amanitin at the indicated concentrations for 5h. Graphs
showing percentages of enucleation in. Data are means (+/− SD) of 3–4 independent experi-
ments analyzed using FACS LSR II (P< 0.05, P< 0.01, P< 0.001, P< 0.0001 (paired
student’s t-test)).
(PDF)
with SNS-032 (1μM); 510–634 cells treated with Dinaciclib (25nM)). Scale bar = 10μm (C)Graph showing the percentages of enucleation after 5h and 10h in
the presence of the indicated compounds (1μM). Data are means (+/− SD) of 3 independent experiments analyzed using FACS LSR II. (D) Compounds were
washed out and replaced by media containing the vehicle control DMSO. Enucleation was assessed by FACS LSR II 0.5h, 1h, 3h and 5h after the washout of
the indicated compounds (1μM). Data are means (+/− SD) of 3 independent experiments analyzed using FACS LSR II.
doi:10.1371/journal.pone.0142655.g004
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S1 Table. Raw data chemical screen targeting erythroid enucleation. The table lists plate ID,
well number, molecular targets, the individual compounds inhibiting these and the corre-
sponding enucleation efficiencies.
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